| Date Filed | Type | Description |
| 06/29/2023 |
4
| AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.|
Txns:
| Sold 759 shares
@ $11.4, valued at
$8.7k
|
|
| 05/24/2023 |
4
| AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.|
Txns:
| Sold 707 shares
@ $9.15, valued at
$6.5k
|
|
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/23/2023 |
4
| AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.|
Txns:
| Granted 109,000 shares
@ $0
Granted 211,000 options to buy
@ $11.03, valued at
$2.3M
|
|
| 07/05/2022 |
4
| AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.|
Txns:
| Granted 1,620 shares
@ $10.9, valued at
$17.7k
|
|
| 06/07/2022 |
4
| AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.|
Txns:
| Bought 8,090 shares
@ $12.4, valued at
$100.3k
|
|
| 03/07/2022 |
4
| AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.|
Txns:
| Granted 215,000 rights
@ $0 |
|
| 10/20/2021 |
4
| AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.|
Txns:
| Granted 2,710,000 options to buy
@ $21.12, valued at
$57.2M
|
|
| 10/20/2021 |
3
| AHMED NADIM (President and CEO) has filed a Form 3 on Cullinan Oncology, Inc. |
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/03/2020 |
4
| AHMED NADIM (EVP and President, Hematology) has filed a Form 4 on BRISTOL MYERS SQUIBB CO|
Txns:
| Paid exercise price by delivering 3,380 shares
@ $62.18, valued at
$210.2k
Exercised 6,594 restricted stock units
@ $0 |
|
| 11/03/2020 |
4
| AHMED NADIM (EVP and President, Hematology) has filed a Form 4 on BRISTOL MYERS SQUIBB CO|
Txns:
| Paid exercise price by delivering 2,291 shares
@ $58.45, valued at
$133.9k
Exercised 4,650 restricted stock units
@ $0 |
|
| 05/05/2020 |
4
| AHMED NADIM (EVP and President, Hematology) has filed a Form 4 on BRISTOL MYERS SQUIBB CO|
Txns:
| Paid exercise price by delivering 1,433 shares
@ $60.26, valued at
$86.4k
Exercised 2,908 restricted stock units
@ $0 |
|
| 03/12/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2020 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 12/04/2019 |
4
| AHMED NADIM (President, Hematology) has filed a Form 4 on BRISTOL MYERS SQUIBB CO|
Txns:
| Granted 26,376 restricted stock units
@ $0 |
|
| 11/27/2019 |
4
| AHMED NADIM (President, Hematology) has filed a Form 4 on BRISTOL MYERS SQUIBB CO|
Txns:
| Granted 4,650 restricted stock units
@ $0
Granted 14,945 restricted stock units
@ $0
Granted 9,965 restricted stock units
@ $0
Granted 6,228 restricted stock units
@ $0
Granted 51,614 restricted stock units
@ $0
Granted 33,182 restricted stock units
@ $0 |
|
| 11/27/2019 |
4
| AHMED NADIM (President, Hematology) has filed a Form 4 on BRISTOL MYERS SQUIBB CO|
Txns:
| Granted 14,819 shares
@ $0
Granted 1,966 shares
@ $0
Granted 3,255 options to buy
@ $19.55, valued at
$63.6k
Granted 10,460 options to buy
@ $19.61, valued at
$205.1k
Granted 10,464 options to buy
@ $19.72, valued at
$206.4k
Granted 16,740 options to buy
@ $21.63, valued at
$362.1k
Granted 10,463 options to buy
@ $26.6, valued at
$278.3k
Granted 6,974 options to buy
@ $31.85, valued at
$222.1k
Granted 6,975 options to buy
@ $38.35, valued at
$267.5k
Granted 6,975 options to buy
@ $42, valued at
$293k
Granted 7,440 options to buy
@ $43.85, valued at
$326.2k
|
|
| 11/27/2019 |
3
| AHMED NADIM (President, Hematology) has filed a Form 3 on BRISTOL MYERS SQUIBB CO |
| 11/22/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/22/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/04/2019 |
4
| AHMED NADIM (PRES., GLOBAL HEM. AND ONC.) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Paid exercise price by delivering 1,096 shares
@ $108.03, valued at
$118.4k
Exercised 3,281 restricted stock units
@ $0 |
|
| 05/06/2019 |
4
| AHMED NADIM (PRES., HEMATOLOGY AND ONCOLOGY) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Paid exercise price by delivering 490 shares
@ $95.21, valued at
$46.7k
Exercised 1,563 restricted stock units
@ $0 |
|
| 03/05/2019 |
4
| AHMED NADIM (PRES., HEMATOLOGY AND ONCOLOGY) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 27,749 restricted stock units
@ $0 |
|
| 02/06/2019 |
4
| AHMED NADIM (PRES., HEMATOLOGY AND ONCOLOGY) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 3,348 restricted stock units
@ $0 |
|
| 12/18/2018 |
4
| AHMED NADIM (PRES., HEMATOLOGY AND ONCOLOGY) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Paid exercise price by delivering 1,477 shares
@ $68.2, valued at
$100.7k
Exercised 3,000 restricted stock units
@ $0 |
|
| 10/31/2018 |
4
| AHMED NADIM (PRES., HEMATOLOGY AND ONCOLOGY) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 10,549 options to buy
@ $71.43, valued at
$753.5k
|
|
| 06/14/2018 |
3
| AHMED NADIM (Pres., Hematology and Oncology) has filed a Form 3 on CELGENE CORP /DE/ |